Mutual of America Capital Management LLC Reduces Position in Regeneron Pharmaceuticals, Inc. $REGN

Mutual of America Capital Management LLC decreased its holdings in shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) by 2.7% in the second quarter, Holdings Channel.com reports. The institutional investor owned 11,892 shares of the biopharmaceutical company’s stock after selling 326 shares during the quarter. Mutual of America Capital Management LLC’s holdings in Regeneron Pharmaceuticals were worth $6,243,000 at the end of the most recent reporting period.

A number of other large investors have also modified their holdings of the business. Arnhold LLC purchased a new stake in shares of Regeneron Pharmaceuticals during the second quarter worth $3,270,000. Citizens Business Bank grew its holdings in shares of Regeneron Pharmaceuticals by 1.9% during the second quarter. Citizens Business Bank now owns 6,125 shares of the biopharmaceutical company’s stock worth $3,216,000 after buying an additional 114 shares in the last quarter. Catawba River Capital grew its holdings in shares of Regeneron Pharmaceuticals by 206.9% during the second quarter. Catawba River Capital now owns 29,676 shares of the biopharmaceutical company’s stock worth $15,580,000 after buying an additional 20,006 shares in the last quarter. Private Trust Co. NA grew its holdings in shares of Regeneron Pharmaceuticals by 16.5% during the second quarter. Private Trust Co. NA now owns 191 shares of the biopharmaceutical company’s stock worth $100,000 after buying an additional 27 shares in the last quarter. Finally, Applied Finance Capital Management LLC grew its holdings in shares of Regeneron Pharmaceuticals by 16.1% during the second quarter. Applied Finance Capital Management LLC now owns 22,983 shares of the biopharmaceutical company’s stock worth $12,066,000 after buying an additional 3,190 shares in the last quarter. Hedge funds and other institutional investors own 83.31% of the company’s stock.

Analyst Upgrades and Downgrades

A number of equities research analysts have recently issued reports on REGN shares. Wells Fargo & Company lowered shares of Regeneron Pharmaceuticals from an “overweight” rating to an “equal weight” rating and set a $580.00 target price for the company. in a report on Friday, August 1st. Raymond James Financial raised shares of Regeneron Pharmaceuticals to a “moderate buy” rating in a report on Tuesday, September 2nd. Rothschild & Co Redburn assumed coverage on shares of Regeneron Pharmaceuticals in a report on Thursday, August 14th. They set a “buy” rating and a $890.00 target price for the company. Royal Bank Of Canada boosted their price target on shares of Regeneron Pharmaceuticals from $688.00 to $695.00 and gave the company a “sector perform” rating in a research report on Monday, August 4th. Finally, Morgan Stanley lowered their price target on shares of Regeneron Pharmaceuticals from $761.00 to $756.00 and set an “overweight” rating on the stock in a research report on Friday, October 10th. Three investment analysts have rated the stock with a Strong Buy rating, eighteen have given a Buy rating, seven have assigned a Hold rating and one has assigned a Sell rating to the company’s stock. According to data from MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and an average target price of $817.88.

Regeneron Pharmaceuticals Trading Up 0.4%

Shares of REGN stock opened at $579.34 on Wednesday. The company’s 50-day moving average price is $575.71 and its 200-day moving average price is $562.26. The company has a current ratio of 4.60, a quick ratio of 3.72 and a debt-to-equity ratio of 0.09. The stock has a market cap of $61.40 billion, a price-to-earnings ratio of 14.60, a PEG ratio of 1.80 and a beta of 0.31. Regeneron Pharmaceuticals, Inc. has a twelve month low of $476.49 and a twelve month high of $972.74.

Regeneron Pharmaceuticals (NASDAQ:REGN) last announced its quarterly earnings results on Friday, August 1st. The biopharmaceutical company reported $12.89 earnings per share for the quarter, beating the consensus estimate of $8.43 by $4.46. The firm had revenue of $3.68 billion for the quarter, compared to analysts’ expectations of $3.30 billion. Regeneron Pharmaceuticals had a net margin of 31.37% and a return on equity of 15.06%. The company’s revenue was up 3.6% compared to the same quarter last year. During the same quarter in the previous year, the company posted $11.56 EPS. As a group, equities analysts predict that Regeneron Pharmaceuticals, Inc. will post 35.92 earnings per share for the current year.

Regeneron Pharmaceuticals Announces Dividend

The business also recently declared a quarterly dividend, which was paid on Wednesday, September 3rd. Shareholders of record on Monday, August 18th were given a dividend of $0.88 per share. The ex-dividend date was Monday, August 18th. This represents a $3.52 dividend on an annualized basis and a dividend yield of 0.6%. Regeneron Pharmaceuticals’s dividend payout ratio (DPR) is currently 8.87%.

About Regeneron Pharmaceuticals

Regeneron Pharmaceuticals, Inc discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity.